War and peace: Factor VIII and the adaptive immune response

Cellular Immunology

Volumn 301, Issue , 2016, Pages 2-7

  Georgescu, Maria T ^a   Lai, Jesse D ^a   Hough, Christine ^a   Lillicrap, David ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Adaptive immune response; B cells; Factor VIII; Hemophilia A; Inhibitors; Plasma cells

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT FACTOR VIII SQ;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CYTOKINE PRODUCTION; EFFECTOR CELL; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PHENOTYPE; PLASMA CELL; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SECONDARY IMMUNE RESPONSE; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ANTIBODIES, NEUTRALIZING; FACTOR VIII; HEMOPHILIA A; HUMANS;

EID: 84959107365     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.11.008     Document Type: Article

References (58)

1. Wroblewska A., Reipert B.M., Pratt K.P., Voorberg J. Dangerous liaisons: how the immune system deals with factor VIII. J. Thromb. Haemost. 2013, 11:47-55. 10.1111/jth.12065.
2. + T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb. Haemost. 2000, 84:643-652.
3. Algiman M., Dietrich G., Nydegger U.E., Boieldieu D., Sultan Y., Kazatchkine M.D. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc. Nat. Acad. Sci. U.S.A. 1992, 89:3795-3799.
4. van Helden P.M.W., Van Haren S.D., Fijnvandraat K., van den Berg H.M., Voorberg J. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors. Haemophilia 2010, 16:35-43. 10.1111/j.1365-2516.2010.02215.x.
5. Bray G.L., Kroner B.L., Arkin S., Aledort L.W., Hilgartner M.W., Eyster M.E., et al. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am. J. Hematol. 1993, 42:375-379.
6. Qian J., Borovok M., Bi L., Kazazian H.H., Hoyer L.W. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb. Haemost. 1999, 81:240-244.
7. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
8. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061. 10.1126/science.1079490.
9. Corthay A. How do regulatory T cells work?. Scand. J. Immunol. 2009, 70:326-336. 10.1111/j.1365-3083.2009.02308.x.
10. Lin X., Chen M., Liu Y., Guo Z., He X., Brand D., et al. Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int. J. Clin. Exp. Path. 2013, 6:116-123.
11. Sakaguchi S., Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T. Regulatory T cells: how do they suppress immune responses?. Int. Immunol. 2009, 21:1105-1111. 10.1093/intimm/dxp095.
12. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787. 10.1016/j.cell.2008.05.009.
13. Whelan S.F.J., Hofbauer C.J., Horling F.M., Allacher P., Wolfsegger M.J., Oldenburg J., et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2012, 121:1039-1048. 10.1182/blood-2012-07-444877.
14. Reding M.T., Lei S., Lei H., Green D., Gill J., Conti-Fine B.M. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb. Haemost. 2002, 88:568-575. 10.1267/th02100568.
15. Hofbauer C.J., Whelan S.F.J., Hirschler M., Allacher P., Horling F.M., Lawo J.-P., et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 2015, 125:1180-1188. 10.1182/blood-2014-09-598268.
16. Rispens T., Ooijevaar-de Heer P., Bende O., Aalberse R.C. Mechanism of immunoglobulin G4 Fab-arm exchange. J. Am. Chem. Soc. 2011, 133:10302-10311. 10.1021/ja203638y.
17. Aalberse R.C., Stapel S.O., Schuurman J., Rispens T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy. 2009, 39:469-477. 10.1111/j.1365-2222.2009.03207.x.
18. van Schouwenburg P.A., Krieckaert C.L., Nurmohamed M., Hart M., Rispens T., Aarden L., et al. IgG4 production against adalimumab during long term treatment of RA patients. J. Clin. Immunol. 2012, 32:1000-1006. 10.1007/s10875-012-9705-0.
19. Gilles J.G., Arnout J., Vermylen J., Saint-Remy J.M. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993, 82:2452-2461.
20. Scandella D., DeGraaf Mahoney S., Mattingly M., Roeder D., Timmons L., Fulcher C.A. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc. Nat. Acad. Sci. U.S.A. 1988, 85:6152-6156.
21. Hay C.R., Ollier W., Pepper L., Cumming A., Keeney S., Goodeve A.C., et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb. Haemost. 1997, 77:234-237.
22. Astermark J., Oldenburg J., Carlson J., Pavlova A., Kavakli K., Berntorp E., et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006, 108:3739-3745. 10.1182/blood-2006-05-024711.
23. Astermark J., Oldenburg J., Pavlova A., Berntorp E., Lefvert A.-K. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, 107:3167-3172. 10.1182/blood-2005-09-3918.
24. Gouw S.C., van den Berg H.M., Fischer K., Auerswald G., Carcao M., Chalmers E., et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013, 121:4046-4055. 10.1182/blood-2012-09-457036.
25. Gouw S.C., van der Bom J.G., Ljung R., Escuriola C., Cid A.R., Claeyssens-Donadel S., et al. Factor VIII products and inhibitor development in severe hemophilia A. N. Engl. J. Med. 2013, 368:231-239. 10.1056/NEJMoa1208024.
26. Qadura M., Waters B., Burnett E., Chegeni R., Hough C., Othman M., et al. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice. Haemophilia 2011, 17:288-295. 10.1111/j.1365-2516.2010.02397.x.
27. Mestas J., Hughes C.C.W. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738. 10.4049/jimmunol.172.5.2731.
28. Jeannin P., Lecoanet S., Delneste Y., Gauchat J.F., Bonnefoy J.Y. IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. 1998, 160:3555-3561.
29. van de Veen W., Stanic B., Yaman G., Wawrzyniak M., Söllner S., Akdis D.G., et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J. Allergy Clin. Immunol. 2013, 131:1204-1212. 10.1016/j.jaci.2013.01.014.
30. Hay C.R.M., DiMichele D.M. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012, 119:1335-1344. 10.1182/blood-2011-08-369132.
31. C. Hausl, R.U. Ahmad, M. Sasgary, C.B. Doering, P. Lollar, H.P. Schwarz, et al., High-dose factor VIII inhibits factor VIII - specific memory B cells in hemophilia A with factor VIII inhibitors, 106 (2005) 3415-3422. doi: . Supported. doi:10.1182/blood-2005-03-1182.
32. Gilles J.G., Desqueper B., Lenk H., Vermylen J., Saint-Remy J.M. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J. Clin. Invest. 1996, 97:1382-1388. 10.1172/JCI118558.
33. Gilles J.G.G., Grailly S.C., De Maeyer M., Jacquemin M.G., VanderElst L.P., Saint-Remy J.-M.R. In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody. Blood 2004, 103:2617-2623. 10.1182/blood-2003-07-2207.
34. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47. 10.1038/nri2206.
35. Antun A., Monahan P.E., Manco-Johnson M.J., Callaghan M.U., Kanin M., Knoll C., et al. Inhibitor recurrence following immune tolerance induction: a multicenter retrospective cohort study. J. Thromb. Haemost. 2015, 10.1111/jth.13143.
36. Carcao M., St Louis J., Poon M.-C., Grunebaum E., Lacroix S., Stain A.M., et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006, 12:7-18. 10.1111/j.1365-2516.2005.01170.x.
37. Maloney D.G., Grillo-López A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
38. Weiner G.J. Rituximab: mechanism of action. Semin. Hematol. 2010, 47:115-123. 10.1053/j.seminhematol.2010.01.011.
39. Zhang A.-H., Skupsky J., Scott D.W. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood 2011, 117:2223-2226. 10.1182/blood-2010-06-293324.
40. Rodriguez V., Mancuso M.E., Warad D., Hay C.R.M., DiMichele D.M., Valentino L., et al. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: lessons from the international immune tolerance study. Haemophilia 2015, 21:e369-e374. 10.1111/hae.12740.
41. Daifotis A.G., Koenig S., Chatenoud L., Herold K.C. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin. Immunol. 2013, 149:268-278. 10.1016/j.clim.2013.05.001.
42. +-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood 2009, 113:193-203. 10.1182/blood-2008-04-151597.
43. Moghimi B., Sack B.K., Nayak S., Markusic D.M., Mah C.S., Herzog R.W. Induction of tolerance to factor VIII by transient co-administration with rapamycin. J. Thromb. Haemost. 2011, 9:1524-1533. 10.1111/j.1538-7836.2011.04351.x.
44. Kim Y.C., Zhang A.-H., Su Y., Rieder S.A., Rossi R.J., Ettinger R.A., et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood 2014, 125:1107-1115. 10.1182/blood-2014-04-566786.
45. M.S. Macauley, F. Pfrengle, C. Rademacher, C.M. Nycholat, A.J. Gale, A. Von Drygalski, et al., Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis, (n.d.) 1-10, doi: . doi:10.1172/JCI69187DS1.
46. Lei T.C., Scott D.W. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005, 105:4865-4870. 10.1182/blood-2004-11-4274.
47. Hausl C., Maier E., Schwarz H.P., Ahmad R.U., Turecek P.L., Dorner F., et al. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb. Haemost. 2002, 87:840-845.
48. Miller J.J. An autoradiographic study of plasma cell and lymphocyte survival in rat lymph nodes. J. Immunol. 1964, 92:673-681.
49. Manz R.A., Thiel A., Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997, 388:133-134. 10.1038/40540.
50. Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 2011, 11:239-253.
51. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916. 10.1182/blood-2005-08-3531.
52. Hideshima T., Richardson P.G., Anderson K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 2011, 10:2034-2042. 10.1158/1535-7163.MCT-11-0433.
53. Meister S., Schubert U., Neubert K., Herrmann K., Burger R., Gramatzki M., et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007, 67:1783-1792. 10.1158/0008-5472.CAN-06-2258.
54. Everly M.J., Everly J.J., Susskind B., Brailey P., Arend L.J., Alloway R.R., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761. 10.1097/TP.0b013e318190af83.
55. Zollner T.M., Podda M., Pien C., Elliott P.J., Kaufmann R., Boehncke W.-H. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J. Clin. Invest. 2002, 109:671-679. 10.1172/JCI12736.
56. Tung D., Cheung P.H., Kaur P., Foreman O., Kavirayani A., Hain H.S., et al. Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology 2011, 88:100-113. 10.1159/000330067.
57. Meslier Y., André S., Dimitrov J.D., Delignat S., Bayry J., Kaveri S.V., et al. Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells. J. Thromb. Haemost. 2011, 9:719-728. 10.1111/j.1538-7836.2011.04200.x.
58. Lonial S. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106:3777-3784. 10.1182/blood-2005-03-1173.